Overview

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of ALKS 5461 on QT intervals in healthy volunteers as well as evaluate the safety and tolerability of ALKS 5461.
Phase:
Phase 1
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination